Article

New drug approved for breast cancer

The FDA approved a new breast cancer chemotherapy today for metastatic disease. Halaven (eribulin), which we covered from the annual ASCO meeting this past summer, made headlines when a phase 3 study showed it extended survival by two and a half months in patients with locally recurrent or metastatic breast cancer that had been treated with multiple therapies. Researchers noted at the meeting that the Halaven study marked the first time a single agent had helped this patient population live longer. The most common side effects of Halaven included fatigue, low white blood cell count and peripheral neuropathy.You can read more about the approval from the FDA here. We will also be covering the new drug in CURE's upcoming breast cancer supplement later next month.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content